CrushSCI.com
136.1平均天数
92中位天数
53最短天数
412最长天数
5772025发文量

Paper Review Records

全部论文审稿周期

11 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

98 天

Real-world treatment patterns and survival outcomes in extensive-stage small cell lung cancer across first-line induction and maintenance therapy

作者
Yi-Shao (Justus) Liu; Parth A Desai; Humera Khurshid; Anne C Chiang; Christine L Hann; Melissa L Johnson; Erik S Anderson; Rani Najdi; Jessie Wang; Xerxes Pundole展开收起
作者单位
1. Amgen Inc, Thousand Oaks, CA 91320, United States; 2. Department of Hematology & Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA 19140, United States; 3. Brown University School of Medicine-Rhode Island Hospital, Providence, RI 02903, United States; 4. Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, United States; 5. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, United States; 6. Sarah Cannon Research Institute, Nashville, TN 37203, United States展开收起
PDF源文件 DOI 网页
92 天

Durable response to vebreltinib in heavily pretreated MET-amplified intrahepatic cholangiocarcinoma: a case report

作者
Yingying Hang; Lu Bai; Hsiquan Hsu; Ying Chen; Fufeng Wang; Wuyan Xu; Xia Zhen; Zihao Wang; Yuan Li; Jun Qian展开收起
作者单位
1. Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Chinese Medicine, Nanjing 210029, China; 2. The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210023, China; 3. Jiangsu Collaborative Innovation Center of TCM Cancer Prevention and Treatment, Nanjing 210023, China; 4. Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing 210032, China; 5. Department of Pathology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China展开收起
官方全文证据 DOI 网页
412 天

Immune checkpoint inhibitors induced autoimmune hemolytic anemia in patients with malignant cancer

作者
Aoxi Liang; Yuanqiang Wu; Shengchi Chen; Jisheng Li; Yue Pan; Yixing Luo; Yue Zeng; Shijiao Yao; Shuxing Wang; Chunhong Hu; Xianling Liu; Fang Wu展开收起
作者单位
1. Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China; 2. Department of Oncology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping 353000, China; 3. Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan 250012, China; 4. Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; 5. Department of Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; 6. Xiangya School of Medicine, Central South University, Changsha 410013, China; 7. Hunan Cancer Mega-Data Intelligent Application and Engineering Research Centre, Changsha 410011, China; 8. Department of Oncology, Guilin Hospital of the Second Xiangya Hospital, Central South University, Guilin 541100, China; 9. Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, China; 10. Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer, The Second Xiangya Hospital, Central South University, Changsha 410011, China; 11. FuRong Laboratory, Changsha 410078, China; 12. Changsha Thoracic Cancer Prevention and Treatment Technology Innovation Center, Changsha 410011, China展开收起
官方全文证据 DOI 网页
173 天

Treatment of metastatic solid pseudopapillary neoplasms

作者
Courtney Porfido; Diane Reidy-Lagunes; Nitya Raj展开收起
作者单位
1. Department of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States; 2. Division of Medical Oncology, Duke Cancer Institute, Durham, NC 27710, United States展开收起
官方全文证据 DOI 网页
79 天

Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation

作者
Galip Can Uyar; Kadriye Başkurt; Orhun Akdoğan; Enes Yeşilbaş; Mustafa Ersoy; Tuba Uğur Tuzcu; Kadriye Bir Yücel; Mustafa Altınbaş; Ömür Berna Çakmak Öksüzoğlu; Gökşen İnanç İmamoğlu; Osman Sütcüoğlu展开收起
作者单位
1. Department of Medical Oncology, Etlik City Hospital, Ankara, 06170, Turkey; 2. Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, 06500, Turkey; 3. Department of Medical Oncology, Kütahya City Hospital, Kütahya, 43100, Turkey展开收起
官方全文证据 DOI 网页
263 天

New prognosis indexes specific to Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma combining functional hepatic reserve and tumor burden

作者
Koji Fujita; Rie Yano; Mai Nakahara; Kyoko Oura; Hironobu Suto; Asahiro Morishita; Takashi Himoto; Keiichi Okano; Hideki Kobara展开收起
作者单位
1. Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu 760-8521, Japan; 2. Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Takamatsu 760-8521, Japan; 3. Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu 761-0123, Japan展开收起
官方全文证据 DOI 网页

FAQ

ONCOLOGIST审稿要多久?

截至2026-11-19,CrushSCI 收录了 ONCOLOGIST 的 11 篇完整审稿记录。最快一篇从收稿到录用用了 53 天(Symptom clusters and quality of life among patients with thyroid cancer during early survivorship: a national multicenter cross-sectional study,2026-06-05 收稿,2026-07-28 录用),最慢一篇用了 412 天;平均 136.1 天,中位数 92 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。